New Data Support Strong Clinical Profile of Vitrakvi® (larotrectinib) for Adult and Pediatric Patients with TRK Fusion Cancer, Including Lung and Thyroid Tumors

WHIPPANY, N.J.--(BUSINESS WIRE)--Updated clinical data for Vitrakvi® (larotrectinib) reinforce the consistent, long-term efficacy and established safety profile in an integrated dataset of 175 adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion cancer.1 In addition, new tumor type specific sub-analyses in lung and thyroid cancer patients further emphasize these durable responses with no new safety signals reported.2,3 These results are being presented at the ESMO Virtual